Therapeutic approaches have been developed to harness the immune-activating functions of IgE for cancer immunotherapy, including: IgE-coated cell vaccines, IgEs as adjuvants, vaccination approaches to trigger IgE-biased immune responses against tumour antigens, and recombinant IgE recognising tumour antigens. The gene discussed is IGHE; the disease is neoplasm.